Par Pharma Begins Shipment of Major Depressive Disorder Drug Khedezla

Osmotica, a partner of Par Pharmaceutical, received FDA clearance of its NDA for Khedezla to treat major depressive disorder. Par has since begun distributing the drug in the U.S. in 50 mg and 100 mg tablets.
Pharmabiz.com